Acurx Pharmaceuticals Inc — Quarterly Cash Flow (NASDAQ:ACXP) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Total assets 5.98 M3.86 M4.81 M6.16 M6.11 M7.69 M Total liabilities 3.32 M3.24 M2.49 M2.59 M2.47 M2.42 M Total equity 2.66 M615.12 K2.31 M3.57 M3.64 M5.27 M Total liabilities & shareholders' equities 5.98 M3.86 M4.81 M6.16 M6.11 M7.69 M Total debt —————— Net debt ——————

Haberler

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript

Acurx Pharmaceuticals 4Ç 2025 sonuçları: Nakit artışı ve Ar-Ge ilerlemesi

Earnings call transcript: Acurx Pharmaceuticals Q4 2025 reveals cash boost and R&D progress

Acurx Pharmaceuticals hisseleri yeni rCDI denemesiyle %3 kazandı

Acurx Pharmaceuticals stock gains over 3% on new rCDI trial launch

What's Going On With Acurx Pharmaceuticals Stock Today? - Acurx Pharmaceuticals (NASDAQ:ACXP)

Why Is Acurx Pharmaceuticals Stock Falling Thursday? - Acurx Pharmaceuticals (NASDAQ:ACXP)

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.61%

Why Is Acurx Pharmaceuticals Stock Up Over 105% Today? - Acurx Pharmaceuticals (NASDAQ:ACXP)

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript

Acurx’ın ibezapolstat ilacı klinik deneylerde mikrobiyom koruyucu özellikler gösteriyor